{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:56:54Z","timestamp":1792144614707,"version":"4.4.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773242"],"award-info":[{"award-number":["81773242"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["32270691"],"award-info":[{"award-number":["32270691"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Identifying the primary site of metastatic cancer is critical to guiding the subsequent treatment. Approximately 3\u20139% of metastatic patients are diagnosed with cancer of unknown primary sites (CUP) even after a comprehensive diagnostic workup. However, a widely accepted molecular test is still not available. Here, we report a method that applies formalin-fixed, paraffin-embedded tissues to construct reduced representation bisulfite sequencing libraries (FFPE-RRBS). We then generate and systematically evaluate 28 molecular classifiers, built on four DNA methylation scoring methods and seven machine learning approaches, using the RRBS library dataset of 498 fresh-frozen tumor tissues from primary cancer patients. Among these classifiers, the\n                    <jats:bold>\n                      <jats:underline>be<\/jats:underline>\n                    <\/jats:bold>\n                    ta value-based\n                    <jats:bold>\n                      <jats:underline>li<\/jats:underline>\n                    <\/jats:bold>\n                    near support\n                    <jats:bold>\n                      <jats:underline>ve<\/jats:underline>\n                    <\/jats:bold>\n                    ctor (BELIVE) performs the best, achieving overall accuracies of 81-93% for identifying the primary sites in 215 metastatic patients using top-k predictions (k\u2009=\u20091, 2, 3). Coincidentally, BELIVE also successfully predicts the tissue of origin in 81-93% of CUP patients (n\u2009=\u200968).\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-41015-0","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T11:00:11Z","timestamp":1694689211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues"],"prefix":"10.1038","volume":"14","author":[{"given":"Shirong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4928-6853","authenticated-orcid":false,"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qionghuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianrang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0528-9048","authenticated-orcid":false,"given":"Ligang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengqing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0039-8800","authenticated-orcid":false,"given":"Jiantao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-7606","authenticated-orcid":false,"given":"Hongcang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"41015_CR1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/cac2.12197","volume":"41","author":"H Qiu","year":"2021","unstructured":"Qiu, H., Cao, S. & Xu, R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun. (Lond) 41, 1037\u20131048 (2021).","journal-title":"Cancer Commun. (Lond)"},{"key":"41015_CR2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"41015_CR3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nrc1886","volume":"6","author":"P Mehlen","year":"2006","unstructured":"Mehlen, P. & Puisieux, A. Metastasis: a question of life or death. Nat. Rev. Cancer 6, 449\u2013458 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"41015_CR4","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","volume":"26","author":"K Fizazi","year":"2015","unstructured":"Fizazi, K. et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26, v133\u2013v138 (2015).","journal-title":"Ann. Oncol."},{"key":"41015_CR5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMra1303917","volume":"371","author":"GR Varadhachary","year":"2014","unstructured":"Varadhachary, G. R. & Raber, M. N. Cancer of unknown primary site. N. Engl J. Med. 371, 757\u2013765 (2014).","journal-title":"N. Engl J. Med."},{"key":"41015_CR6","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","volume":"17","author":"S Moran","year":"2016","unstructured":"Moran, S. et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 17, 1386\u20131395 (2016).","journal-title":"Lancet Oncol"},{"key":"41015_CR7","doi-asserted-by":"crossref","first-page":"vii303","DOI":"10.1093\/annonc\/mdq278","volume":"21","author":"N Pavlidis","year":"2010","unstructured":"Pavlidis, N. & Pentheroudakis, G. Cancer of unknown primary site: 20 questions to be answered. Ann. Oncol. 21, vii303\u2013vii307 (2010).","journal-title":"Ann. Oncol."},{"key":"41015_CR8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/cancers13030451","volume":"13","author":"N Laprovitera","year":"2021","unstructured":"Laprovitera, N. et al. Cancer of unknown primary: challenges and progress in clinical management. Cancers (Basel) 13, 451 (2021).","journal-title":"Cancers (Basel)"},{"key":"41015_CR9","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s11864-013-0257-1","volume":"14","author":"FA Greco","year":"2013","unstructured":"Greco, F. A. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management. Curr. Treat Options Oncol. 14, 634\u2013642 (2013).","journal-title":"Curr. Treat Options Oncol."},{"key":"41015_CR10","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3389\/fonc.2019.01546","volume":"9","author":"S Kolling","year":"2019","unstructured":"Kolling, S. et al. \u201cMetastatic Cancer of Unknown Primary\u201d or \u201cPrimary Metastatic Cancer\u201d? Front. Oncol. 9, 1546 (2019).","journal-title":"Front. Oncol."},{"key":"41015_CR11","doi-asserted-by":"crossref","first-page":"e13583","DOI":"10.1111\/eci.13583","volume":"51","author":"E Rassy","year":"2021","unstructured":"Rassy, E., Boussios, S. & Pavlidis, N. Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary. Eur. J. Clin. Invest. 51, e13583 (2021).","journal-title":"Eur. J. Clin. Invest."},{"key":"41015_CR12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clcc.2011.08.001","volume":"11","author":"JD Hainsworth","year":"2012","unstructured":"Hainsworth, J. D. et al. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin. Colorectal Cancer 11, 112\u2013118 (2012).","journal-title":"Clin. Colorectal Cancer"},{"key":"41015_CR13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(08)70151-7","volume":"9","author":"GR Varadhachary","year":"2008","unstructured":"Varadhachary, G. R. et al. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol. 9, 596\u2013599 (2008).","journal-title":"Lancet Oncol."},{"key":"41015_CR14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","volume":"31","author":"JD Hainsworth","year":"2013","unstructured":"Hainsworth, J. D. et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J. Clin. Oncol. 31, 217\u2013223 (2013).","journal-title":"J. Clin. Oncol."},{"key":"41015_CR15","doi-asserted-by":"crossref","first-page":"102407","DOI":"10.1016\/j.ctrv.2022.102407","volume":"107","author":"E Rassy","year":"2022","unstructured":"Rassy, E. et al. Systematic review of the CUP trials characteristics and perspectives for next-generation studies. Cancer Treat. Rev. 107, 102407 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"41015_CR16","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/pon.3244","volume":"22","author":"T Hyphantis","year":"2013","unstructured":"Hyphantis, T. et al. Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. Psychooncology 22, 2009\u20132015 (2013).","journal-title":"Psychooncology"},{"key":"41015_CR17","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.6004\/jnccn.2011.0117","volume":"9","author":"DS Ettinger","year":"2011","unstructured":"Ettinger, D. S. et al. NCCN Clinical Practice Guidelines Occult primary. J. Natl Compr. Canc. Netw. 9, 1358\u20131395 (2011).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"41015_CR18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/EDBK_100014","volume":"38","author":"JD Hainsworth","year":"2018","unstructured":"Hainsworth, J. D. & Greco, F. A. Cancer of unknown primary site: new treatment paradigms in the era of precision medicine. Am. Soc. Clin. Oncol. Educ. Book 38, 20\u201325 (2018).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"41015_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/PAI.0b013e3181a75e6d","volume":"18","author":"GG Anderson","year":"2010","unstructured":"Anderson, G. G. & Weiss, L. M. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl. Immunohistochem. Mol. Morphol. 18, 3\u20138 (2010).","journal-title":"Appl. Immunohistochem. Mol. Morphol"},{"key":"41015_CR20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12094-011-0679-9","volume":"13","author":"A Ariza","year":"2011","unstructured":"Ariza, A. et al. Update on the diagnosis of cancer of unknown primary (CUP) origin. Clin. Transl. Oncol. 13, 434\u2013441 (2011).","journal-title":"Clin. Transl. Oncol."},{"key":"41015_CR21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.trecan.2020.11.002","volume":"7","author":"S Kato","year":"2021","unstructured":"Kato, S. et al. Cancer of unknown primary in the molecular era. Trends Cancer 7, 465\u2013477 (2021).","journal-title":"Trends Cancer"},{"key":"41015_CR22","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2007.14.4378","volume":"26","author":"GR Varadhachary","year":"2008","unstructured":"Varadhachary, G. R. et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J. Clin. Oncol. 26, 4442\u20134448 (2008).","journal-title":"J. Clin. Oncol."},{"key":"41015_CR23","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1200\/JCO.2007.14.6969","volume":"26","author":"HM Horlings","year":"2008","unstructured":"Horlings, H. M. et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J. Clin. Oncol. 26, 4435\u20134441 (2008).","journal-title":"J. Clin. Oncol."},{"key":"41015_CR24","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1634\/theoncologist.2009-0328","volume":"15","author":"FA Greco","year":"2010","unstructured":"Greco, F. A. et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 15, 500\u2013506 (2010).","journal-title":"Oncologist"},{"key":"41015_CR25","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1158\/1078-0432.CCR-10-2599","volume":"17","author":"GR Varadhachary","year":"2011","unstructured":"Varadhachary, G. R. et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin. Cancer Res. 17, 4063\u20134070 (2011).","journal-title":"Clin. Cancer Res."},{"key":"41015_CR26","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/modpathol.2010.57","volume":"23","author":"S Rosenwald","year":"2010","unstructured":"Rosenwald, S. et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod. Pathol. 23, 814\u2013823 (2010).","journal-title":"Mod. Pathol."},{"key":"41015_CR27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5858\/2006-130-465-MCOHCU","volume":"130","author":"XJ Ma","year":"2006","unstructured":"Ma, X. J. et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch. Pathol. Lab. Med. 130, 465\u2013473 (2006).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"41015_CR28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jmoldx.2010.11.001","volume":"13","author":"R Pillai","year":"2011","unstructured":"Pillai, R. et al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J. Mol. Diagn. 13, 48\u201356 (2011).","journal-title":"J. Mol. Diagn."},{"key":"41015_CR29","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1158\/1078-0432.CCR-12-0920","volume":"18","author":"SE Kerr","year":"2012","unstructured":"Kerr, S. E. et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin. Cancer Res. 18, 3952\u20133960 (2012).","journal-title":"Clin. Cancer Res."},{"key":"41015_CR30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jmoldx.2011.04.004","volume":"13","author":"MG Erlander","year":"2011","unstructured":"Erlander, M. G. et al. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J. Mol. Diagn. 13, 493\u2013503 (2011).","journal-title":"J. Mol. Diagn."},{"key":"41015_CR31","first-page":"574398","volume":"2009","author":"SC Tan","year":"2009","unstructured":"Tan, S. C. & Yiap, B. C. DNA, RNA, and protein extraction: the past and the present. J. Biomed. Biotechnol. 2009, 574398 (2009).","journal-title":"J. Biomed. Biotechnol."},{"key":"41015_CR32","first-page":"1","volume":"4","author":"LG Legres","year":"2014","unstructured":"Legres, L. G. et al. Beyond laser microdissection technology: follow the yellow brick road for cancer research. Am. J. Cancer Res. 4, 1\u201328 (2014).","journal-title":"Am. J. Cancer Res."},{"key":"41015_CR33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/labinvest.3700529","volume":"87","author":"SK Penland","year":"2007","unstructured":"Penland, S. K. et al. RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab. Invest. 87, 383\u2013391 (2007).","journal-title":"Lab. Invest."},{"key":"41015_CR34","doi-asserted-by":"crossref","first-page":"10807","DOI":"10.1021\/bi00034a013","volume":"34","author":"EA Lesnik","year":"1995","unstructured":"Lesnik, E. A. & Freier, S. M. Relative thermodynamic stability of DNA, RNA, and DNA:RNA hybrid duplexes: relationship with base composition and structure. Biochemistry 34, 10807\u201310815 (1995).","journal-title":"Biochemistry"},{"key":"41015_CR35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00019606-199612000-00002","volume":"5","author":"DH Farkas","year":"1996","unstructured":"Farkas, D. H. et al. Specimen stability for DNA-based diagnostic testing. Diagn. Mol. Pathol. 5, 227\u2013235 (1996).","journal-title":"Diagn. Mol. Pathol."},{"key":"41015_CR36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature12433","volume":"500","author":"MJ Ziller","year":"2013","unstructured":"Ziller, M. J. et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 500, 477\u2013481 (2013).","journal-title":"Nature"},{"key":"41015_CR37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1101\/gr.119867.110","volume":"22","author":"AF Fernandez","year":"2012","unstructured":"Fernandez, A. F. et al. A DNA methylation fingerprint of 1628 human samples. Genome Res. 22, 407\u2013419 (2012).","journal-title":"Genome Res."},{"key":"41015_CR38","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2014-15-4-r54","volume":"15","author":"K Lokk","year":"2014","unstructured":"Lokk, K. et al. DNA methylome profiling of human tissues identifies global and tissue-specific methylation patterns. Genome Biol. 15, r54 (2014).","journal-title":"Genome Biol."},{"key":"41015_CR39","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1038\/sj.onc.1205651","volume":"21","author":"M Ehrlich","year":"2002","unstructured":"Ehrlich, M. DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400\u20135413 (2002).","journal-title":"Oncogene"},{"key":"41015_CR40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg1655","volume":"6","author":"KD Robertson","year":"2005","unstructured":"Robertson, K. D. DNA methylation and human disease. Nat. Rev. Genet. 6, 597\u2013610 (2005).","journal-title":"Nat. Rev. Genet."},{"key":"41015_CR41","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrclinonc.2017.97","volume":"14","author":"S Moran","year":"2017","unstructured":"Moran, S. et al. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat. Rev. Clin. Oncol. 14, 682\u2013694 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"41015_CR42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nmeth.1414","volume":"7","author":"H Gu","year":"2010","unstructured":"Gu, H. et al. Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. Nat. Methods 7, 133\u2013136 (2010).","journal-title":"Nat. Methods"},{"key":"41015_CR43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nprot.2010.190","volume":"6","author":"H Gu","year":"2011","unstructured":"Gu, H. et al. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat. Protoc. 6, 468\u2013481 (2011).","journal-title":"Nat. Protoc."},{"key":"41015_CR44","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2012-13-10-r92","volume":"13","author":"P Boyle","year":"2012","unstructured":"Boyle, P. et al. Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling. Genome Biol. 13, R92 (2012).","journal-title":"Genome Biol"},{"key":"41015_CR45","first-page":"1","volume":"27","author":"W Chen","year":"2015","unstructured":"Chen, W. Cancer statistics: updated cancer burden in China. Chin. J. Cancer Res. 27, 1 (2015).","journal-title":"Chin. J. Cancer Res."},{"key":"41015_CR46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/bio.2012.0052","volume":"11","author":"TJ Kokkat","year":"2013","unstructured":"Kokkat, T. J. et al. Archived formalin-fixed paraffin-embedded (FFPE) blocks: A valuable underexploited resource for extraction of DNA, RNA, and protein. Biopreserv. Biobank 11, 101\u2013106 (2013).","journal-title":"Biopreserv. Biobank"},{"key":"41015_CR47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/10520295.2018.1446101","volume":"93","author":"EF Gaffney","year":"2018","unstructured":"Gaffney, E. F. et al. Factors that drive the increasing use of FFPE tissue in basic and translational cancer research. Biotech. Histochem. 93, 373\u2013386 (2018).","journal-title":"Biotech. Histochem."},{"key":"41015_CR48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/cncr.11464","volume":"98","author":"SD Nathanson","year":"2003","unstructured":"Nathanson, S. D. Insights into the mechanisms of lymph node metastasis. Cancer 98, 413\u2013423 (2003).","journal-title":"Cancer"},{"key":"41015_CR49","doi-asserted-by":"crossref","first-page":"e0176280","DOI":"10.1371\/journal.pone.0176280","volume":"12","author":"N Einaga","year":"2017","unstructured":"Einaga, N. et al. Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation. PLoS ONE 12, e0176280 (2017).","journal-title":"PLoS ONE"},{"key":"41015_CR50","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jmoldx.2013.05.004","volume":"15","author":"DH Spencer","year":"2013","unstructured":"Spencer, D. H. et al. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J. Mol. Diagn. 15, 623\u2013633 (2013).","journal-title":"J. Mol. Diagn."},{"key":"41015_CR51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41586-021-03512-4","volume":"594","author":"MY Lu","year":"2021","unstructured":"Lu, M. Y. et al. AI-based pathology predicts origins for cancers of unknown primary. Nature 594, 106\u2013110 (2021).","journal-title":"Nature"},{"key":"41015_CR52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamaoncol.2019.3985","volume":"6","author":"A Penson","year":"2020","unstructured":"Penson, A. et al. Development of genome-derived tumor type prediction to inform clinical cancer care. JAMA Oncol. 6, 84\u201391 (2020).","journal-title":"JAMA Oncol"},{"key":"41015_CR53","volume":"11","author":"W Jiao","year":"2020","unstructured":"Jiao, W. et al. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 11, 728 (2020).","journal-title":"Nat Commun."},{"key":"41015_CR54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ymeth.2009.05.003","volume":"48","author":"ZD Smith","year":"2009","unstructured":"Smith, Z. D. et al. High-throughput bisulfite sequencing in mammalian genomes. Methods 48, 226\u2013232 (2009).","journal-title":"Methods"},{"key":"41015_CR55","doi-asserted-by":"crossref","first-page":"103030","DOI":"10.1016\/j.ebiom.2020.103030","volume":"61","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. EBioMedicine 61, 103030 (2020).","journal-title":"EBioMedicine"},{"key":"41015_CR56","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5858\/2008-132-326-UTTIBI","volume":"132","author":"A Bahrami","year":"2008","unstructured":"Bahrami, A., Truong, L. D. & Ro, J. Y. Undifferentiated tumor: true identity by immunohistochemistry. Arch. Pathol. Lab. Med. 132, 326\u2013348 (2008).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"41015_CR57","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-021-00342-4","volume":"9","author":"A Balian","year":"2021","unstructured":"Balian, A. & Hernandez, F. J. Nucleases as molecular targets for cancer diagnosis. Biomark. Res. 9, 86 (2021).","journal-title":"Biomark. Res."},{"key":"41015_CR58","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.critrevonc.2020.103208","volume":"158","author":"S Boussios","year":"2021","unstructured":"Boussios, S. et al. Melanoma of unknown primary: new perspectives for an old story. Crit. Rev. Oncol. Hematol. 158, 103208 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"41015_CR59","doi-asserted-by":"crossref","first-page":"102882","DOI":"10.1016\/j.critrevonc.2020.102882","volume":"147","author":"E Rassy","year":"2020","unstructured":"Rassy, E. et al. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit? Crit. Rev. Oncol. Hematol. 147, 102882 (2020).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"41015_CR60","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","volume":"28","author":"AM Varghese","year":"2017","unstructured":"Varghese, A. M. et al. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Ann. Oncol. 28, 3015\u20133021 (2017).","journal-title":"Ann. Oncol."},{"key":"41015_CR61","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ejca.2022.06.017","volume":"172","author":"A Chebly","year":"2022","unstructured":"Chebly, A. et al. Chromosomal instability in cancers of unknown primary. Eur. J. Cancer 172, 323\u2013325 (2022).","journal-title":"Eur. J. Cancer"},{"key":"41015_CR62","doi-asserted-by":"crossref","first-page":"21 4 1","DOI":"10.1002\/0471142735.im2104s103","volume":"103","author":"FM Hofman","year":"2013","unstructured":"Hofman, F. M. & Taylor, C. R. Immunohistochemistry. Curr. Protoc. Immunol. 103, 21 4 1\u201321 4 26 (2013).","journal-title":"Curr. Protoc. Immunol."},{"key":"41015_CR63","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-019-1198-z","volume":"569","author":"F Gaiti","year":"2019","unstructured":"Gaiti, F. et al. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature 569, 576\u2013580 (2019).","journal-title":"Nature"},{"key":"41015_CR64","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1038\/s41596-021-00571-9","volume":"16","author":"H Gu","year":"2021","unstructured":"Gu, H. et al. Smart-RRBS for single-cell methylome and transcriptome analysis. Nat. Protoc. 16, 4004\u20134030 (2021).","journal-title":"Nat. Protoc."},{"key":"41015_CR65","volume":"10","author":"Y Xi","year":"2009","unstructured":"Xi, Y. & Li, W. BSMAP: whole genome bisulfite sequence MAPping program. BMC Bioinformatics 10, 232 (2009).","journal-title":"BMC Bioinformatics"},{"key":"41015_CR66","doi-asserted-by":"crossref","unstructured":"Zhang, Z. et al. The DNA methylation haplotype (mHap) format and mHapTools. Bioinformatics 37, 4892\u20134894 (2021).","DOI":"10.1093\/bioinformatics\/btab458"},{"key":"41015_CR67","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-016-1347-4","volume":"17","author":"L Weinhold","year":"2016","unstructured":"Weinhold, L. et al. A statistical model for the analysis of beta values in DNA methylation studies. BMC Bioinformatics 17, 480 (2016).","journal-title":"BMC Bioinformatics"},{"key":"41015_CR68","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ccell.2014.10.012","volume":"26","author":"DA Landau","year":"2014","unstructured":"Landau, D. A. et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 26, 813\u2013825 (2014).","journal-title":"Cancer Cell"},{"key":"41015_CR69","volume":"12","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. Cellular Heterogeneity-Adjusted cLonal Methylation (CHALM) improves prediction of gene expression. Nat. Commun. 12, 400 (2021).","journal-title":"Nat. Commun"},{"key":"41015_CR70","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ng.3805","volume":"49","author":"S Guo","year":"2017","unstructured":"Guo, S. et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat. Genet. 49, 635\u2013642 (2017).","journal-title":"Nat. Genet."},{"key":"41015_CR71","doi-asserted-by":"publisher","unstructured":"Zhang, S. R. et al. DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues. Zenodo https:\/\/doi.org\/10.5281\/zenodo.8022705 (2023).","DOI":"10.5281\/zenodo.8022705"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41015-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T08:20:39Z","timestamp":1700122839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41015-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["41015"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-41015-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"28 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Q.X., Y.W., and C.X. are full-time employees of Zhejiang ShengTing Biotech. H.G. is a co-founder of Zhejiang ShengTing Biotech. All other authors reported no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5686"}}